Organogenesis Holdings Inc.
NASDAQ:ORGODrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $110.75M
- Beta
- 1.33
- P/E (TTM)
- -1086.7
- EPS (TTM)
- -$0.00
Volume 0.86M
Average 1.49M
ORGO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Organogenesis Holdings Inc.NASDAQ: ORGO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $12.37M rose 96.9% year over year, ahead of the +70.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 76.4% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.
Context
- Depreciation & amortization amounted to 4.8% of revenue in FY2025, up 1.3 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +96.9% holds above the trailing-twelve-month pace of +70.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 26.94M USD
- Year-over-year change
- +58.2%
- 4-year CAGR
- +12.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.94M | +58.2% |
| FY2024 | 2024-12-31 | 17.03M | -27.4% |
| FY2023 | 2023-12-31 | 23.45M | +30.0% |
| FY2022 | 2022-12-31 | 18.03M | +8.1% |
| FY2021 | 2021-12-31 | 16.68M | — |
Depreciation & Amortization vs competitors
How ORGO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +70.8% is the highest of 10, against a peer median of -0.7%.
- Depreciation & amortization amounts to 6.4% of revenue for ORGO, versus a peer median of 4.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $95.4M USD | -8.8% | -7.7% | 14.1% | |
| LTM Mar 2026 | CA$56.2M CAD | -0.2% | +5.9% | 6.0% | |
| LTM Mar 2026 | $33.03M USD | +70.8% | +14.3% | 6.4% | |
| LTM Apr 2026 | $27.1M USD | -0.7% | -6.8% | 3.2% | |
| LTM Feb 2026 | $23.26M USD | -13.2% | -4.2% | 7.4% | |
| LTM Mar 2026 | $9.28M USD | +53.3% | +32.9% | 3.1% | |
| LTM Mar 2026 | $5.92M USD | -17.6% | +20.3% | 9.3% | |
| LTM Mar 2026 | $1.12M USD | -32.0% | -8.2% | — | |
| LTM Mar 2026 | $577.25K USD | +7.8% | +2.8% | 0.6% | |
| LTM Mar 2026 | $106K USD | +19.1% | -40.6% | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding ORGO) | — | -0.7% | -4.2% | 4.6% | |
Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 467.36M | 450.89M | 433.14M | 482.04M | 563.03M |
| Cost of Revenue | 114.2M | 105.02M | 106.48M | 115.74M | 137.52M |
| Gross Profit | 353.16M | 345.87M | 326.66M | 366.3M | 425.51M |
| Gross Margin | 75.6% | 76.7% | 75.4% | 76.0% | 75.6% |
| Research & Development | 30.74M | 39.76M | 44.38M | 50.27M | 44.54M |
| Selling, General & Admin | 250.2M | 283.81M | 269.75M | 294.51M | 326.24M |
| Operating Expenses | 280.94M | 323.57M | 314.13M | 367.59M | 369.64M |
| Depreciation & Amortization | 16.68M | 18.03M | 23.45M | 17.03M | 26.94M |
| EBITDA | 87M | 40.32M | 36.03M | 15.76M | 73.91M |
| EBITDA Margin | 18.6% | 8.9% | 8.3% | 3.3% | 13.1% |
| Operating Income | 72.22M | 22.3M | 12.53M | (1.28M) | 55.87M |
| Operating Margin | 15.5% | 4.9% | 2.9% | -0.3% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 2.28M |
| Interest Expense | 7.24M | 2.01M | 2.19M | 1.54M | 0 |
| Other Income / Expenses | (9.13M) | (2.02M) | (2.13M) | (1.52M) | (8.9M) |
| Income Before Tax | 63.09M | 20.28M | 10.39M | (2.81M) | 46.97M |
| Pre-Tax Margin | 13.5% | 4.5% | 2.4% | -0.6% | 8.3% |
| Income Tax Expense | (31.12M) | 4.75M | 5.45M | (3.67M) | 9.94M |
| Net Income | 94.2M | 15.53M | 4.95M | 861K | 37.03M |
| Net Margin | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| EPS (Basic) | 0.73 | 0.12 | 0.04 | (0.01) | 0.16 |
| EPS (Diluted) | 0.70 | 0.12 | 0.04 | (0.01) | 0.15 |
| Weighted Avg Shares | 128.33M | 130.07M | 131.23M | 131.67M | 126.74M |
| Weighted Avg Shares (Diluted) | 133.66M | 132.38M | 132.75M | 131.67M | 130.25M |
Organogenesis Holdings Inc.
NASDAQ:ORGO
Intrinsic Alpha fair value
Locked
Current Price
$0.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.